Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Silpa Narayanan, Chao‐Yun Cai, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2019) Vol. 48, pp. 100663-100663
Closed Access | Times Cited: 251

Showing 1-25 of 251 citing articles:

Glioma targeted therapy: insight into future of molecular approaches
Keyang Yang, Zhijing Wu, Hao Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 476
Anticancer drug resistance: An update and perspective
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang
Drug Resistance Updates (2021) Vol. 59, pp. 100796-100796
Open Access | Times Cited: 248
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Jinyun Dong, Zuodong Qin, Weidong Zhang, et al.
Drug Resistance Updates (2020) Vol. 49, pp. 100681-100681
Closed Access | Times Cited: 209
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
Yaël Cohen, Mor Zada, Shuang-Yin Wang, et al.
Nature Medicine (2021) Vol. 27, Iss. 3, pp. 491-503
Open Access | Times Cited: 182
Therapeutic strategies to overcome taxane resistance in cancer
Tuyelee Das, Uttpal Anand, Swaroop Kumar Pandey, et al.
Drug Resistance Updates (2021) Vol. 55, pp. 100754-100754
Closed Access | Times Cited: 150
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification
Bowen Li, Jingwen Jiang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100720-100720
Closed Access | Times Cited: 140
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis
Jan M. Griffin, Hannah Rosenblum, Matthew J. Maurer
Circulation Research (2021) Vol. 128, Iss. 10, pp. 1554-1575
Open Access | Times Cited: 112
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
Maohua Huang, Yuning Lin, Chenran Wang, et al.
Drug Resistance Updates (2022) Vol. 64, pp. 100849-100849
Closed Access | Times Cited: 96
PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer
Liliang Shen, Junfeng Zhang, Zongtai Zheng, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 14, pp. 5459-5474
Open Access | Times Cited: 85
Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers
Yuanfang Li, Baiwei Zhao, Juzheng Peng, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101042-101042
Open Access | Times Cited: 33
Cancer plasticity in therapy resistance: Mechanisms and novel strategies
Xing Niu, Wenjing Liu, Zhang Yinling, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101114-101114
Closed Access | Times Cited: 15
Platinum nanoparticles in cancer therapy: chemotherapeutic enhancement and ROS generation
Emmanuel Faderin, Terungwa H. Iorkula, Omowunmi Rebecca Aworinde, et al.
Medical Oncology (2025) Vol. 42, Iss. 2
Closed Access | Times Cited: 2
The combination of disulfiram and copper for cancer treatment
Hong Li, Jingyu Wang, Chunfu Wu, et al.
Drug Discovery Today (2020) Vol. 25, Iss. 6, pp. 1099-1108
Closed Access | Times Cited: 130
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
Lingyue Gao, Zhuo‐Xun Wu, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2021) Vol. 57, pp. 100770-100770
Closed Access | Times Cited: 96
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
Grazia R. Tundo, Diego Sbardella, Anna Maria Santoro, et al.
Pharmacology & Therapeutics (2020) Vol. 213, pp. 107579-107579
Open Access | Times Cited: 86
Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study
Ya Cao, Longlong Xie, Feng Shi, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 80
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
Michele Dal Bo, Elena De Mattia, Lorena Baboçi, et al.
Drug Resistance Updates (2020) Vol. 51, pp. 100702-100702
Open Access | Times Cited: 76
Ubiquitin-Specific Proteases: Players in Cancer Cellular Processes
Lucas Lopes Cruz, Paula Soares, Marcelo Correia
Pharmaceuticals (2021) Vol. 14, Iss. 9, pp. 848-848
Open Access | Times Cited: 64
DRESIS: the first comprehensive landscape of drug resistance information
Xiuna Sun, Yintao Zhang, Hanyang Li, et al.
Nucleic Acids Research (2022) Vol. 51, Iss. D1, pp. D1263-D1275
Open Access | Times Cited: 56
Biological and pharmacological roles of m6A modifications in cancer drug resistance
Zaoqu Liu, Haijiao Zou, Qin Dang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 52
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability
Giasemi C. Eptaminitaki, Dimitris Stellas, Benjamin Bonavida, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100866-100866
Closed Access | Times Cited: 51
Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis
Longfei Yang, Yuwei Zhang, Yang Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 49
AZGP1P2/UBA1/RBM15 Cascade Mediates the Fate Determinations of Prostate Cancer Stem Cells and Promotes Therapeutic Effect of Docetaxel in Castration-Resistant Prostate Cancer via TPM1 m6A Modification
Hong Wang, Liu Ji, Xiaojun Zhu, et al.
Research (2023) Vol. 6
Open Access | Times Cited: 32
Triazole-fused pyrimidines in target-based anticancer drug discovery
Xing‐Jie Dai, Lei-Peng Xue, Shi‐Kun Ji, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115101-115101
Closed Access | Times Cited: 31
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
Xiangyu Sun, Ping Zhao, Jierou Lin, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 2, pp. 390-415
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top